Signal transducer and activator of transcription 5B-DNA interaction at the Human epidermal growth factor receptor 2 promoter (STAT5B-HER2 promoter interaction)

The STAT5b-DNA interaction at the HER2 promoter is a molecular mechanism where the transcription factor Signal Transducer and Activator of Transcription 5B (STAT5b) binds to the promoter of the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) gene to drive its expression (Yamashita et al., 2004). This interaction is particularly significant in breast cancer, where STAT5b activation by prolactin or other growth factors leads to increased HER2 levels, contributing to tumor progression and therapeutic resistance (Clevenger et al., 2008). STAT5b binds to specific Gamma-Interferon Activation Sites (GAS) within the HER2 promoter, acting as a direct transcriptional activator (Kazansky et al., 1995). Because HER2 is a major oncogenic driver, the STAT5b-mediated regulation of its transcription represents a potential therapeutic target for downregulating HER2 in cancers that have become resistant to direct HER2 inhibitors (Wang et al., 2015). Small molecule inhibitors such as Pimozide and more selective agents like Stafib-2 aim to disrupt STAT5b signaling, thereby preventing its binding to the HER2 promoter and subsequent gene activation (Nelson et al., 2011; Müller et al., 2008). This target is of high interest in the context of HER2-positive breast cancers that develop resistance to trastuzumab or lapatinib through compensatory signaling pathways. By inhibiting the transcriptional source of HER2, researchers hope to achieve more complete suppression of the HER2 signaling axis. Therapeutic challenges include the high homology between STAT5a and STAT5b and the potential for systemic toxicity due to the role of STAT5 in normal hematopoiesis and immune function.

Other names

STAT5B binding to ERBB2 promoterSTAT5B-mediated HER2 transcriptionSTAT5B-HER2 axisSTAT5B-ERBB2 interaction

Inhibition of STAT5B phosphorylation, dimerization, or DNA binding activity to prevent the transcriptional activation of the HER2 gene (Nelson et al., 2011; Müller et al., 2008).